News
BIVI
--
0.00%
--
BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit
BioVie Inc., (NASDAQ: BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurodegenerative disorders and advanced liver disease, today announced the participation of its management team in t...
GlobeNewswire · 3d ago
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8)
Benzinga · 09/09 12:17
swisspartners Ltd. Buys Stellantis NV, Deere, The Mosaic Co, Sells Stellantis NV, Zoetis Inc,
GuruFocus News · 08/13 15:38
BioVie Inc. Announces Closing of Public Offering of Common Stock
BioVie Inc., (NASDAQ: BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, today announced the closing of its u...
GlobeNewswire · 08/11 17:14
BioVie Closes Common Stock Offering
MT Newswires · 08/11 14:35
68 Biggest Movers From Yesterday
Gainers
Benzinga · 08/10 09:17
Mid-Afternoon Market Update: Aterian Falls After Q2 Results; Select Interior Concepts Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.17% to 35,150.02 while the NASDAQ rose 0.26% to 14,874.23. The S&P also rose, gaining 0.01% to 4,436.62.
Benzinga · 08/09 18:35
SCWorx, Liminal BioSciences leads healthcare gainers; Axsome Therapeutics, BioVie among major losers
Gainers: SCWorx (NASDAQ:WORX) +32%, Liminal BioSciences (NASDAQ:LMNL) +28%, Allied Healthcare Products (NASDAQ:AHPI) +20%, Windtree Therapeutics (NASDAQ:WINT) +17%, NRx Pharmaceuticals (NASDAQ:NRXP) +15%. Losers: Axsome Therapeutics (NASDAQ:AXSM) -42%, Bio...
Seekingalpha · 08/09 15:03
Elanco Animal Health, Avaya Holdings, Axsome Therapeutics among premarket losers' pack
Axsome Therapeutics (NASDAQ:AXSM) -43% on Q2 earnings release and on likely delay in potential approval of AXS-05; depression study meets endpoints BioVie (NASDAQ:BIVI) -35% after secures $20M via equity raise Aterian (NASDAQ:ATER) -31% on Q2 earnings
Seekingalpha · 08/09 12:32
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 08/09 12:09
Update: BioVie Prices Offering at $8/Share, Expects $20 Million Gross Proceeds - Shares Slump
MT Newswires · 08/09 11:20
BioVie Stock Plunges On $20M Capital Raise Via Equity At Deep Discount Of 38%
Benzinga · 08/09 11:04
20 Stocks Moving in Monday's Pre-Market Session
Gainers Windtree Therapeutics, Inc. (NASDAQ: WINT) shares rose 55.8% to $2.82 in pre-market trading after dropping over 10% on Friday. The company recently reported a wider loss for its second quarter.
Benzinga · 08/09 11:03
BioVie Prices Offering at $8/Share, Expects $20 Million Gross Proceeds
MT Newswires · 08/09 03:50
BioVie secures $20M via equity raise
BioVie (NASDAQ:BIVI) has priced its public offering of 2.5M shares of Class A common stock at $8.00/share, for gross proceeds of  $20M. Underwriters' over-allotment is an additional 375K shares. Net
Seekingalpha · 08/09 03:47
BRIEF-Biovie Inc. Announces Pricing Of Public Offering Of Common Stock
reuters.com · 08/09 01:29
BioVie Inc. Announces Pricing of Public Offering of Common Stock
BioVie Inc., (NASDAQ: BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, today announced the pricing of its u...
GlobeNewswire · 08/09 01:28
BRIEF-BioVie Announces Proposed Public Offering Of Common Stock
reuters.com · 08/06 21:31
BioVie Inc. Announces Proposed Public Offering of Common Stock
SANTA MONICA, Calif., Aug. 06, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease a...
GlobeNewswire · 08/06 21:30
Webull provides a variety of real-time BIVI stock news. You can receive the latest news about BioVie through multiple platforms. This information may help you make smarter investment decisions.
About BIVI
BioVie Inc. clinical-stage company pursuing the discovery, development, and commercialization of drug therapies for liver disease. The Company is focused on developing and commercializing BIV201 (continuous infusion terlipressin) an approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The Company is developing BIV201, a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH) and alcoholism. The Company is also engaged in developing NE3107, an ERK inhibitor that selectively reduces neuroinflammation and insulin resistance.